Table 2.
Pulmonary arterial hypertension-specific therapy: A summary of agents used
Entothelin receptor antagonists |
Agents used in PoPHT: bosentan, ambrisentan |
Mechanism of action: blockade of endothelin receptors |
Route of administration: oral |
Effects: vasodilation, decrease in PVR and portal pressure |
Adverse effects: hepatotoxicity |
PDE-5 inhibitors |
Agents used in PoPHT: sildenafil, tadalafil, vardenafil |
Mechanism of action: inhibition of PDE-5 enzyme |
Route of administration: oral |
Effects: vasodilation, decrease in portal pressure |
Adverse effects: hypotension |
Prostacyclins |
Agents used in PoPHT: epoprostenol, iloprost |
Mechanism of action: prostaglandin analogue, increase in cAMP |
Route of administration: epoprostenol IV, iloprost inhalation |
Effects: vasodilation, antiaggregation |
Adverse effects: flushing, headache, nausea, diarrhea. Problems with IV epoprostenol use: cost, infection, catheter thrombosis, and thrombocytopenia |
PAH: Pulmonary arterial hypertension; PoPHT: Portopulmonary hypertension; PDE-5: Phosphodiesterase type 5 enzyme; PVR: Pulmonary vascular resistance; IV: Intravenous.